Literature DB >> 1649148

Local immunotherapy (beta-IFN) and systemic chemotherapy in primary glial tumors.

A Boiardi1, A Silvani, I Milanesi, L Munari, G Broggi, M Botturi.   

Abstract

Dosage and schedules for the treatment of malignant glial tumors using IFN (interferon) are still uncertain and controversial. In this study we give the preliminary results of treatment in 28 patients with glioblastoma multiforme (GBM). 6 patients were treated with local injection of beta-IFN through an Ommaya reservoir; 4 patients with beta-IFN followed by systemic chemotherapy (Cisplatin + Etoposide), and 18 patients with chemotherapy only. Two end points were evaluated: 1) Whether or not the patients responded to treatment. 2) Length of Time to Tumor Progression (TTP) after surgery. We found that IFN alone was ineffective. Results were improved when local immunotherapy was associated with systemic chemotherapy. New drugs and investigation of possible pharmacological synergism are needed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649148     DOI: 10.1007/bf02337028

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  15 in total

1.  Block of glioma cell line in S by interferon.

Authors:  D Lundblad; E Lundgren
Journal:  Int J Cancer       Date:  1981-06-15       Impact factor: 7.396

2.  Interferon effects on multiplication, cytoplasmic protein and GFAP content, and morphology in human glioma cells.

Authors:  K Korosue; I Takeshita; H Mannoji; M Fukui
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

3.  [Interferon therapy for primary brain tumors (Part II). DNA analysis and mean survival time].

Authors:  Y Nakagawa
Journal:  Neurol Med Chir (Tokyo)       Date:  1984-02       Impact factor: 1.742

Review 4.  [Interferon therapy for malignant brain tumors-present and future (author's transl)].

Authors:  M Nagai; T Arai
Journal:  No Shinkei Geka       Date:  1982-05

5.  Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice.

Authors:  I Gresser; C Maury; M Tovey
Journal:  Eur J Cancer       Date:  1978-01       Impact factor: 9.162

6.  [rInterferon-alpha A (Ro 22-8181) therapy for patients with malignant brain tumors].

Authors:  S Otsuka; J Yamashita; A Keyaki; H Handa
Journal:  Gan To Kagaku Ryoho       Date:  1984-05

7.  [Effect of human fibroblast interferon on malignant brain tumors].

Authors:  O Nakamura; A Teramoto; H Yamamoto; C Ochiai; K Takakura; K Maruo; Y Ueyama; K Shimamura
Journal:  No To Shinkei       Date:  1983-09

8.  [Combination therapy with IFN-beta, ACNU and radiation (IAR) in malignant brain tumors].

Authors:  J Yoshida; T Wakabayashi; K Kato; H Enomoto; A Kito; N Kageyama
Journal:  Gan To Kagaku Ryoho       Date:  1986-03

9.  The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme.

Authors:  J Boëthius; H Blomgren; V P Collins; T Greitz; H Strander
Journal:  Acta Neurochir (Wien)       Date:  1983       Impact factor: 2.216

10.  Single agent therapy of interferon for brain tumours: correlation between natural killer activity and clinical course.

Authors:  S Otsuka; H Handa; J Yamashita; K Suda; J Takeuchi
Journal:  Acta Neurochir (Wien)       Date:  1984       Impact factor: 2.216

View more
  1 in total

Review 1.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.